Drug intelligence / Profile preview

mepivacaine hydrochloride + epinephrine

Development stage
Unknown
Lead developer
DLA Pharmaceutical
Modality
Small Molecules
Administration
Submucosal
01

Overview

Mepivacaine hydrochloride + epinephrine is a combination pharmaceutical product used for local anesthesia, particularly in dental procedures. Mepivacaine is an amide-type local anesthetic that works by binding to and blocking voltage-gated sodium channels on the neuronal membrane, which prevents the initiation and conduction of nerve impulses. Epinephrine is a sympathomimetic amine that acts as a vasoconstrictor; it is included in the formulation to decrease local blood flow, thereby delaying the systemic absorption of mepivacaine, prolonging its anesthetic effect, and reducing the risk of systemic toxicity. This specific combination (2% mepivacaine with 1:100,000 epinephrine) is frequently used in clinical research, such as studies conducted by the University of Nove de Julho, to evaluate techniques like photobiomodulation for reducing injection-related pain.

Brand names
Mepiadre
Other names
Mepivacaine 2% with Epinephrine 1:100,000mepivacaine hydrochloride + epinephrine-University of Nove de Julho
02

Targets

ADRB2 (β2)NaV (Voltage-gated sodium channels)ADRA2A (α2A)ADRA1A (α1A)ADRB1 (β1)

Beyond the preview

Go deeper on mepivacaine hydrochloride + epinephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mepivacaine hydrochloride + epinephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call